Watchlists Portfolios Alerts Sign in Get started

Menu

Market-Moving News for February 5th

Benzinga Newsdesk Feb 5, 2024 2 years ago

MoversTrading Ideas

FDMT: 86% | 4DMT Presents Interim Data From Randomized Phase 2 PRISM Clinical Trial Of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity In Wet AMD BRTX: 74%

FDMT: 86% | 4DMT Presents Interim Data From Randomized Phase 2 PRISM Clinical Trial Of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity In Wet AMD

BRTX: 74% | BioRestorative Therapies Presented At The Orthopaedic Research Society 2024 Annual Meeting, Which Describes Preliminary 26 And 52 Week Blinded Data From The Ongoing Phase 2 Trial Of BRTX-100, In Subjects With Chronic Lumbar Disc Disease

CDIO: 33% | Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests

Read the original